• Explore /
  • Poster
  • / Interim analysis of IMMUNEBOOST-HPV: A multicenter, randomized, open label, phase II study evaluating the feasibility, and tolerance of neoadjuvant nivolumab in high-risk HPV driven oropharynx cancer.

Interim analysis of IMMUNEBOOST-HPV: A multicenter, randomized, open label, phase II study evaluating the feasibility, and tolerance of neoadjuvant nivolumab in high-risk HPV driven oropharynx cancer.

Abstract Poster

Authors

null

Haitham Mirghani

Hôpital Européen Georges Pompidou HEGP, Paris, France

Haitham Mirghani , Caroline Even , Alicia Larive , Jerome Fayette , Karen Benezery , Florian Clatot , Lionnel Geoffrois , Yungan Tao , France Nguyen , Emmanuelle Fabiano , Sarah Kreps , Eve Marie Neidhardt , Florence Garic , Anne Auperin , Pierre Blanchard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03838263

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6037)

DOI

10.1200/JCO.2021.39.15_suppl.6037

Abstract #

6037

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Chiara Mercinelli

First Author: Jiwei Huang

First Author: Rohit K. Jain

First Author: Jhe-Cyuan Guo